Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines Journal Article

  

Authors:	König, A.; Wrazel, L.; Warrell, R. P. Jr; Rivi, R.; Pandolfi, P. P.; Jakubowski, A.; Gabrilove, J. L.
Article Title:	Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines
Abstract:	Inorganic arsenic trioxide (As2O3) was recently shown to induce apoptosis in NB4 promyelocytic leukemic cells. We have investigated the effects of the organic arsenical, melarsoprol (a drug used for treatment of trypanosomiasis), upon induction of apoptosis in cell lines representative of chronic B-cell lymphoproliferative disorders. An Epstein-Barr virus (EBV)- transformed B-prolymphocytic cell line (JVM-2), an EBV-transformed B-cell chronic lymphocytic leukemia (B-CLL) cell line (183CLL), and one non-EBV- transformed B-CLL cell line (WSU-CLL) were used as targets. Dose-response experiments with melarsoprol (10-7 to 10-9 mol/L) were performed over 96 hours. Unexpectedly, we found that melarsoprol caused a dose- and time- dependent inhibition of survival and growth in all three cell lines. In contrast, As2O3 at similar concentrations had no effect on either viability or growth. After 24 hours, all three cell lines treated with melarsoprol (10-7 mol/L) exhibited morphologic characteristics of apoptosis. We also observed prominent concentration-dependent downregulation of bcl-2 mRNA after 24 hours of exposure to melarsoprol in WSU-CLL, 183CLL, and JVM-2 cells. Decrease of bcl-2 protein expression was also observed in all three cell lines, whereas As2O3 had no effect on this parameter. We conclude that melarsoprol; may inhibit the growth of lymphoid leukemic cell by promoting programmed cell death. Results of these studies suggest that melarsoprol shows promising therapeutic activity in these diseases, and a study to evaluate clinical effects of this drug has been initiated.
Keywords:	protein expression; human cell; dose response; antineoplastic agents; cell death; cell viability; dna damage; cell survival; cell division; apoptosis; transcription, genetic; drug screening assays, antitumor; tumor cells, cultured; time factors; arsenic trioxide; arsenicals; oxides; kinetics; rna, messenger; promyelocytic leukemia; cell line, transformed; lymphoproliferative disease; chronic lymphatic leukemia; proto-oncogene proteins c-bcl-2; concentration response; herpesvirus 4, human; growth inhibition; b cell leukemia; dna fragmentation; dose time effect relation; humans; human; priority journal; article; leukemia, b-cell, chronic; melarsoprol; arsenic poisoning
Journal Title:	Blood
Volume:	90
Issue:	2
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	1997-07-15
Start Page:	562
End Page:	570
Language:	English
PUBMED:	9226155
PROVIDER:	scopus
DOI:	10.1182/blood.V90.2.562
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-0038125071&partnerID=40&md5=878748b75b1b038c7d7d1de155bd77c8
Notes:	Article -- Export Date: 17 March 2017 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/107609